JIA uveitis — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Switch to weekly subcutaneous methotrexate at an optimised dose
Subcutaneous methotrexate can improve tolerability and exposure when oral treatment is limited by nausea or incomplete response. Weekly administration and paediatric weight or surface-area dosing must be preserved, with ongoing blood monitoring and escalation if the optimised trial fails.
Reference: 2025 BSR guideline for prescription and monitoring of conventional synthetic DMARDs (Published November 2025): https://academic.oup.com/rheumatology/article/65/2/keaf522/8322743; BNF: methotrexate (Current BNF monograph, accessed 30 July 2026): https://bnf.nice.org.uk/drugs/methotrexate/